ImmuPharma (LON:IMM) Shares Down 4.5% – Should You Sell?

ImmuPharma plc (LON:IMMGet Free Report)’s share price traded down 4.5% during trading on Wednesday . The stock traded as low as GBX 2.82 ($0.03) and last traded at GBX 2.94 ($0.04). 2,099,809 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 19,547,262 shares. The stock had previously closed at GBX 3.08 ($0.04).

ImmuPharma Trading Up 13.3 %

The stock has a market capitalization of £16.99 million, a price-to-earnings ratio of -408.00 and a beta of 1.53. The stock has a 50-day moving average price of GBX 1.71 and a 200 day moving average price of GBX 1.72.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Read More

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.